会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明申请
    • INHIBITORS AND SUBSTRATES OF THROMBIN
    • 抑制剂和硫蛋白基质
    • WO1992007869A1
    • 1992-05-14
    • PCT/GB1991001946
    • 1991-11-06
    • THROMBOSIS RESEARCH INSTITUTEKAKKAR, Vijay, VirDEADMAN, John, JosephCLAESON, Goran, KarlCHENG, LeifengCHINO, NaoyashiELGENDY, Said, Mohamed, AnwarSCULLY, Michael, Finbarr
    • THROMBOSIS RESEARCH INSTITUTE
    • C07K05/08
    • C07K5/0207A61K38/00C07K5/0202C07K5/06008C07K5/06191C07K5/0812C07K7/02Y02P20/55
    • Peptides which act as inhibitors or substrates of thrombin are derived from the formula: D-Phe-Pro-Arg or its analogues, wherein Phe is substituted by (a), wherein Ar1 and Ar2 are the same or different and are selected from the group consisting of phenyl, thienyl, pyridyl, naphthyl, thionaphthyl, indolyl and saturated groups corresponding to these, optionally substituted by up to three groups selected from C1-C3 alkyl and C1-C3 alkoxy, L1 and L2 are the same of different and are selected from the group consisting of CH2, CH2-CH2, O-CH2, S-CH2, Ar-L taken together optionally means H, diphenyl-methyl, fluorenyl or saturated groups corresponding to these, but one of the Ar-L cannot be H when the other Ar-L means H or benzyl, and Arg may be substituted by an amino acid of formula (b), wherein Y = [CH2]n-Q, (c), where Q = H, amino, amidino, imidazole, guanidino or isothioureido and n = 1-5, preferably 3-5, or C3-C9 alkyl and C5-C10 aryl or alkylaryl optionally substituted by up to three groups selected from hydroxy and C1-C4 alkoxy; Z = CN, COR1, (d) or (e), where R1 = H, OH, CH2Cl, CH2-CH2-CO-pip, CF2-CF2-CO-pip, (f), (g), CH2-CH2-CO-Pro-NHEt, CF2-CF2-CO-Pro-NHEt or a chromophoric group e.g. pNA, MCA, R2 and R3 are the same or different and are selected from the group consisting of OH, OR6 and NR6R7, or R2 and R3 taken together represent the residue of a diol; where R6 and R7, which are the same or different, are C1-C10 alkyl, phenyl or C6-C10 arylalkyl, R4 and R5 are the same or different and are selected from R2, R3, Gly-pip, Ala-pip or Gly-Pro-NHEt.
    • 作为抑制剂或凝血酶底物的肽衍生自下式:D-Phe-Pro-Arg或其类似物,其中Phe被(a)取代,其中Ar1和Ar2相同或不同,并且选自 由对应于它们的苯基,噻吩基,吡啶基,萘基,萘基,吲哚基和饱和基团任选被至多三个选自C 1 -C 3烷基和C 1 -C 3烷氧基的基团取代,L 1和L 2是不同的并且被选择 由CH 2,CH 2 -CH 2,O-CH 2,S-CH 2,Ar-L组成的基团任选地表示H,二苯基甲基,芴基或对应于它们的饱和基团,但Ar-L中的一个不能是H 当另一个Ar-L表示H或苄基,并且Arg可以被式(b)的氨基酸取代,其中Y = [CH 2] nQ,(c)其中Q = H,氨基,脒基,咪唑,胍基 或异硫脲基,n = 1-5,优选3-5,或C 3 -C 9烷基和C 5 -C 10芳基或烷基芳基,任选被至多三个 选自羟基和C 1 -C 4烷氧基; Z = CN,COR1,(d)或(e),其中R1 = H,OH,CH2Cl,CH2-CH2-CO-pip,CF2-CF2-CO-pip,(f),(g),CH2-CH2 -CO-Pro-NHEt,CF2-CF2-CO-Pro-NHEt或发色团 pNA,MCA,R2和R3相同或不同,选自OH,OR 6和NR 6 R 7,或者R 2和R 3一起代表二醇的残基; 其中R 6和R 7相同或不同,为C 1 -C 10烷基,苯基或C 6 -C 10芳基烷基,R 4和R 5相同或不同,并且选自R 2,R 3,Gly-pip,Ala-pip或Gly -Pro-NHEt。